Literature DB >> 19363652

Chemokines as possible targets in modulation of the secondary damage after acute spinal cord injury: a review.

Peter Gál1, Petra Kravcuková, Michal Mokrý, Darina Kluchová.   

Abstract

In spite of many promising experimental studies, an effective treatment dramatically eliminating the secondary damage after spinal cord injury (SCI) is still missing. Since clinical data on the therapeutical effect after methylprednisolone treatment are not conclusive, new therapeutical modalities targeting specific components of secondary spinal cord damage needs to be developed. It is known that immune cells are recruited to injury sites by chemokines, which are small, structurally similar proteins released locally at the site of inflammation. Hence, this review was aimed to summarize possible roles of chemokines in the inflammation following SCI as well as to identify possible new therapeutical targets which can potentially be effective in ameliorating individual components of this inflammatory response. Data concerning inflammation reduction together with techniques improving axonal growth, cell replacement and remyelinization, may be crucial to move a small step forward in an attempt to make paraplegic and quadriplegic patients to walk.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19363652     DOI: 10.1007/s10571-009-9392-4

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  107 in total

1.  Editorial: recommendations regarding the use of methylprednisolone in acute spinal cord injury: making sense out of the controversy.

Authors:  M G Fehlings
Journal:  Spine (Phila Pa 1976)       Date:  2001-12-15       Impact factor: 3.468

Review 2.  Experimental strategies to promote spinal cord regeneration--an integrative perspective.

Authors:  Jan M Schwab; Klaus Brechtel; Christian-Andreas Mueller; Vieri Failli; Hans-Peter Kaps; Sagun K Tuli; Hermann J Schluesener
Journal:  Prog Neurobiol       Date:  2006-02-17       Impact factor: 11.685

3.  TAK-220, a novel small-molecule CCR5 antagonist, has favorable anti-human immunodeficiency virus interactions with other antiretrovirals in vitro.

Authors:  Cécile L Tremblay; Françoise Giguel; Yongbiao Guan; Ting-Chao Chou; Katsunori Takashima; Martin S Hirsch
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

4.  A neutrophil elastase inhibitor (ONO-5046) reduces neurologic damage after spinal cord injury in rats.

Authors:  T Tonai; K Shiba; Y Taketani; Y Ohmoto; K Murata; M Muraguchi; H Ohsaki; E Takeda; T Nishisho
Journal:  J Neurochem       Date:  2001-09       Impact factor: 5.372

5.  Spinal cord injury-induced expression of the immune-regulatory chemokine interleukin-16 caused by activated microglia/macrophages and CD8+ cells.

Authors:  Christian A Mueller; Hermann J Schluesener; Sabine Conrad; Torsten Pietsch; Jan M Schwab
Journal:  J Neurosurg Spine       Date:  2006-03

6.  Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12),Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection.

Authors:  H Tamamura; M Imai; T Ishihara; M Masuda; H Funakoshi; H Oyake; T Murakami; R Arakaki; H Nakashima; A Otaka; T Ibuka; M Waki; A Matsumoto; N Yamamoto; N Fujii
Journal:  Bioorg Med Chem       Date:  1998-07       Impact factor: 3.641

7.  Characterization of the early neuroinflammation after spinal cord injury in mice.

Authors:  Tiffany Rice; Jennifer Larsen; Serge Rivest; V Wee Yong
Journal:  J Neuropathol Exp Neurol       Date:  2007-03       Impact factor: 3.685

8.  Identification of potent, selective non-peptide CC chemokine receptor-3 antagonist that inhibits eotaxin-, eotaxin-2-, and monocyte chemotactic protein-4-induced eosinophil migration.

Authors:  J R White; J M Lee; K Dede; C S Imburgia; A J Jurewicz; G Chan; J A Fornwald; D Dhanak; L T Christmann; M G Darcy; K L Widdowson; J J Foley; D B Schmidt; H M Sarau
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

9.  Causes and costs of spinal cord injury in the United States.

Authors:  M J DeVivo
Journal:  Spinal Cord       Date:  1997-12       Impact factor: 2.772

10.  Spinal cord restitution following compression injuries in rats.

Authors:  B Nyström; J E Berglund
Journal:  Acta Neurol Scand       Date:  1988-12       Impact factor: 3.209

View more
  11 in total

1.  Neuroprotective effects of sildenafil in experimental spinal cord injury in rabbits.

Authors:  Hasan Kara; Selim Degirmenci; Ahmet Ak; Aysegul Bayir; Seyit Ali Kayis; Mehmet Uyar; Murat Akinci; Demet Acar; Metin Kocacan; Fikret Akyurek
Journal:  Bosn J Basic Med Sci       Date:  2015-01-08       Impact factor: 3.363

2.  Neuroprotective effect of ginseng against spinal cord injury induced oxidative stress and inflammatory responses.

Authors:  Wei Wang; Hao Shen; Jing-Jing Xie; Jian Ling; Hua Lu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  The non-psychoactive phytocannabinoid cannabidiol (CBD) attenuates pro-inflammatory mediators, T cell infiltration, and thermal sensitivity following spinal cord injury in mice.

Authors:  Hongbo Li; Weimin Kong; Christina R Chambers; Daohai Yu; Doina Ganea; Ronald F Tuma; Sara Jane Ward
Journal:  Cell Immunol       Date:  2018-03-08       Impact factor: 4.868

4.  Modulation of inflammatory responses by a cannabinoid-2-selective agonist after spinal cord injury.

Authors:  Sabina Adhikary; Hongbo Li; Joshua Heller; Mario Skarica; Ming Zhang; Doina Ganea; Ronald F Tuma
Journal:  J Neurotrauma       Date:  2011-10-04       Impact factor: 5.269

5.  B-Cell Depletion with CD20 Antibodies as New Approach in the Treatment of Inflammatory and Immunological Events Associated with Spinal Cord Injury.

Authors:  Giovanna Casili; Daniela Impellizzeri; Marika Cordaro; Emanuela Esposito; Salvatore Cuzzocrea
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

6.  Evaluating the role of IL-11, a novel cytokine in the IL-6 family, in a mouse model of spinal cord injury.

Authors:  Newton Cho; Dung H Nguyen; Kajana Satkunendrarajah; Donald R Branch; Michael G Fehlings
Journal:  J Neuroinflammation       Date:  2012-06-20       Impact factor: 8.322

7.  CCL28 promotes locomotor recovery after spinal cord injury via recruiting regulatory T cells.

Authors:  Pengfei Wang; Xiangbei Qi; Guohui Xu; Jianning Liu; Jichao Guo; Xu Li; Xinzhe Ma; Hui Sun
Journal:  Aging (Albany NY)       Date:  2019-09-26       Impact factor: 5.682

8.  Blocking neurogenic inflammation for the treatment of acute disorders of the central nervous system.

Authors:  Kate Marie Lewis; Renée Jade Turner; Robert Vink
Journal:  Int J Inflam       Date:  2013-05-29

Review 9.  Inflammation & apoptosis in spinal cord injury.

Authors:  Ning Zhang; Ying Yin; Sheng-Jie Xu; Yong-Ping Wu; Wei-Shan Chen
Journal:  Indian J Med Res       Date:  2012-03       Impact factor: 2.375

10.  Does combined therapy of curcumin and epigallocatechin gallate have a synergistic neuroprotective effect against spinal cord injury?

Authors:  Jiri Ruzicka; Lucia Machova Urdzikova; Barbora Svobodova; Anubhav G Amin; Kristyna Karova; Jana Dubisova; Kristyna Zaviskova; Sarka Kubinova; Meic Schmidt; Meena Jhanwar-Uniyal; Pavla Jendelova
Journal:  Neural Regen Res       Date:  2018-01       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.